Sandrock Alfred 4

What Happened Alfred Sandrock, President & CEO and a director of Voyager Therapeutics (VYGR), sold 12,192 shares of common stock on February 10, 2026. The sales generated proceeds of $46,086 based on a weighted-average price of $3.78 per share; individual sale prices ranged from $3.68 to $3.91. According to the filing, the sales were made to satisfy tax withholding obligations related to restricted stock units that vested on February 9, 2026 and were not discretionary trades by the reporting person.

Key Details

• Transaction type: Sale (sell-to-cover for tax withholding following RSU vesting)
• Transaction date: February 10, 2026; Form 4 filed February 11, 2026 (timely)
• Shares sold: 12,192
• Price: Weighted average $3.78; range $3.68–$3.91
• Proceeds: $46,086 (gross)
• Shares owned after transaction: Not disclosed in the provided filing
• Footnotes: F1 — sale pursuant to durable automatic sales instruction to satisfy tax withholding; F2 — weighted-average price reported, seller can provide per-price breakdown on request
• Filing timeliness: No late filing indicated

Context This was a routine sell-to-cover (tax withholding) tied to RSU vesting, not an independent open-market decision to reduce a stake. Such transactions are common when restricted shares vest and generally reflect tax mechanics rather than a signal about the insider's view of the company.